Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (161-170 of 302) with videos related to

Pageof 31
Sort By:
Cancer Chemotherapy and Pharmacology|May 23, 2007
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancerRamesh K Ramanathan, Joel Picus, Haralambos Raftopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePTH S Hochster, A Grothey, L Hart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumorsJulie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Cancer Chemotherapy and Pharmacology|April 29, 2009
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancersAfshin Dowlati, James Posey, Ramesh K Ramanathan, et al.
Journal of Cancer|September 11, 2012
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trialsMitesh J Borad, Kelly K Curtis, Hani M Babiker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerRichard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerRichard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Oncology|March 5, 2009
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancerJoanna M Brell, Khalid Matin, Terry Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinomaMace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2014
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumorsKelly K Curtis, John Sarantopoulos, Donald W Northfelt, et al.
Pageof 31

Showing results (161-170 of 302) with videos related to

Sort By:
Pageof 31
Cancer Chemotherapy and Pharmacology|May 23, 2007
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancerRamesh K Ramanathan, Joel Picus, Haralambos Raftopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePTH S Hochster, A Grothey, L Hart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumorsJulie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Cancer Chemotherapy and Pharmacology|April 29, 2009
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancersAfshin Dowlati, James Posey, Ramesh K Ramanathan, et al.
Journal of Cancer|September 11, 2012
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trialsMitesh J Borad, Kelly K Curtis, Hani M Babiker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerRichard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerRichard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Oncology|March 5, 2009
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancerJoanna M Brell, Khalid Matin, Terry Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinomaMace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2014
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumorsKelly K Curtis, John Sarantopoulos, Donald W Northfelt, et al.
Pageof 31